LLM Job #14286 - score_story_relevance
Conversation
You are a financial news analyst. Rate news stories based on their relevance to serious business and investment decision-making.
Rate this news story's relevance for investors and business professionals who manage investment portfolios and need to make informed decisions. This is ONE news story covered by MULTIPLE news sources. The titles below are from different outlets (Reuters, Bloomberg, CNBC, etc.) all reporting on the SAME business event. Rate the overall story's relevance. Article Titles: 1. FDA Approves First CAR T-Cell Therapy for Marginal Zone Lymphoma In the US 2. FDA Approves CAR-T Therapy for Marginal Zone Lymphoma 3. FDA nod for Breyanzi as first CAR T therapy for r/r marginal zone lymphoma 4. BMS wins fifth US approval for CAR T cell therapy Breyanzi 5. Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) 6. FDA Approves Lisocabtagene Maraleucel for Relapsed/Refractory Marginal Zone Lymphoma Scoring Guidelines: - 9-10: Critical business news (earnings reports, Fed decisions, major M&A, sector-wide impact, regulatory changes) - 7-8: Important analysis (market trends, analyst insights, significant company developments, economic indicators) - 5-6: Relevant news (notable company announcements, industry developments, financial performance) - 3-4: Minor business news (routine updates, small moves, tangential business stories) - 1-2: Fluff/entertainment (celebrity CEO drama, viral marketing, cultural controversies, consumer complaints) High-value examples: - "Wall Street Sentiment on AI Companies Shifts as Earnings Disappoint" (9-10) - "Federal Reserve Minutes Reveal Concerns About Inflation Persistence" (9-10) - "Apple Supplier Cuts Production by 20% Amid Weak iPhone Demand" (8-9) - "Banking Sector Faces Regulatory Scrutiny After Failed Stress Tests" (8-9) Low-value examples: - "Starbucks Cup Design Sparks Outrage on Social Media" (1-2) - "CEO's Dog Makes Appearance at Company Event" (1-2) - "Company Changes Office Snack Selection" (1-2)
{
"explanation": "This news story is highly relevant to investors and business professionals managing investment portfolios, particularly in the healthcare and biotechnology sectors. The FDA approval of lisocabtagene maraleucel (Breyanzi) as the first and only CAR T-cell therapy for adults with relapsed or refractory marginal zone lymphoma (MZL) represents a significant regulatory milestone for Bristol Myers Squibb (BMS). This approval expands the commercial applicability of a high-value, innovative therapy in a niche but growing oncology segment, with implications for market share, revenue potential, and competitive positioning in the $10B+ CAR T-cell therapy market. The event signals clinical and commercial validation of a targeted treatment in a rare blood cancer, which may influence investor sentiment toward BMS and other players in the immuno-oncology space. Given the high cost and long-term value of CAR T therapies, this approval could impact pricing, reimbursement dynamics, and future R\u0026D investment trends. As such, it qualifies as critical business news with sector-wide implications.\n\nThe fact that multiple reputable outlets (Reuters, Bloomberg, CNBC) are covering the same event underscores its significance and broad market relevance.\n\nAdditionally, the approval of a fifth US indication for Breyanzi strengthens BMS’s leadership in the CAR T space—important for portfolio managers tracking biotech innovation and commercialization timelines.\n\nTherefore, this story is best rated as 9-10: Critical business news.",
"score": 9
}Debug Information
▶ Structured Output Schema (JSON Schema)
{
"json_schema": {
"description": "Business relevance score for a news story",
"name": "story_relevance",
"schema": {
"additionalProperties": false,
"properties": {
"explanation": {
"description": "1-2 sentence explanation of the score",
"type": "string"
},
"score": {
"description": "Relevance score (1-10)",
"maximum": 10,
"minimum": 1,
"type": "integer"
}
},
"required": [
"score",
"explanation"
],
"type": "object"
},
"strict": true
},
"type": "json_schema"
}▶ Token Usage & Performance
{
"completion_tokens": 313,
"predicted_ms": 0,
"prompt_ms": 0,
"prompt_tokens": 516,
"total_tokens": 829
}▶ Context & Parameters (Full JSON)
{
"article_count": 6,
"explanation": "This news story is highly relevant to investors and business professionals managing investment portfolios, particularly in the healthcare and biotechnology sectors. The FDA approval of lisocabtagene maraleucel (Breyanzi) as the first and only CAR T-cell therapy for adults with relapsed or refractory marginal zone lymphoma (MZL) represents a significant regulatory milestone for Bristol Myers Squibb (BMS). This approval expands the commercial applicability of a high-value, innovative therapy in a niche but growing oncology segment, with implications for market share, revenue potential, and competitive positioning in the $10B+ CAR T-cell therapy market. The event signals clinical and commercial validation of a targeted treatment in a rare blood cancer, which may influence investor sentiment toward BMS and other players in the immuno-oncology space. Given the high cost and long-term value of CAR T therapies, this approval could impact pricing, reimbursement dynamics, and future R\u0026D investment trends. As such, it qualifies as critical business news with sector-wide implications.\n\nThe fact that multiple reputable outlets (Reuters, Bloomberg, CNBC) are covering the same event underscores its significance and broad market relevance.\n\nAdditionally, the approval of a fifth US indication for Breyanzi strengthens BMS’s leadership in the CAR T space—important for portfolio managers tracking biotech innovation and commercialization timelines.\n\nTherefore, this story is best rated as 9-10: Critical business news.",
"finish_reason": "stop",
"google_story_id": 18178,
"max_tokens": 2000,
"relevance_score": 9,
"response_format": "json_schema",
"response_format_details": {
"json_schema": {
"description": "Business relevance score for a news story",
"name": "story_relevance",
"schema": {
"additionalProperties": false,
"properties": {
"explanation": {
"description": "1-2 sentence explanation of the score",
"type": "string"
},
"score": {
"description": "Relevance score (1-10)",
"maximum": 10,
"minimum": 1,
"type": "integer"
}
},
"required": [
"score",
"explanation"
],
"type": "object"
},
"strict": true
},
"type": "json_schema"
},
"temperature": 0
}